Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis

Philpott, Holly T.; O’Brien, Melissa; McDougall, Jason J.

doi:10.1097/j.pain.0000000000001052

Cited by 201 publications

(150 citation statements)

References 43 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…82 SB366791 was also effective in reversing CBD's suppression of rolling and adherent leukocytes in the sodium monoiodoacetate model of osteoarthritis in rats. 83 Together, these data suggest that TRPV1 is a critical receptor through which CBD acts in the immune system.…”

Section: Identification Of Cbd Receptors and Other Targetsmentioning

confidence: 91%

“…67 Since anandamide exhibits affinity for CB 1 and CB 2 receptors, and oxidation products of anandamide through cyclooxygenase or cytochrome P450 enzymes produce metabolites that also exhibit affinity for CB 1 and CB 2 receptors, 70,71 anandamide or its metabolites could account for some of the reports that CBD acts through CB 1 and/or CB 2 receptors. 58,[61][62][63][64][72][73][74][75][76][77][78][79][80][81][82][83][84] Actions of CBD in immune function might also be mediated by the transient receptor potential V1, known as the vanilloid receptor (TRPV1), which was found to be activated by CBD. 65 Specifically, CBD was found to increase intracellular calcium in HEK cells transfected with TRPV1, and the CBD-induced increase in calcium was blocked by the TRPV1 antagonist, capsazepine.…”

Section: Identification Of Cbd Receptors and Other Targetsmentioning

confidence: 99%

See 1 more Smart Citation

Immune Responses Regulated by Cannabidiol

Nichols

Kaplan

2020

Cannabis and Cannabinoid Research

199

176

View full text Add to dashboard Cite

Introduction: Cannabidiol (CBD) as Epidiolex Ò (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabis and CBD oil for putative medical use in many states, the exposure to CBD is increasing, even though all of its biological effects are not understood. Once such example is the ability of CBD to be anti-inflammatory and immune suppressive, so the purpose of this review is to summarize effects and mechanisms of CBD in the immune system. It includes a consideration of reports identifying receptors through which CBD acts, since the ' 'CBD receptor,' ' if a single one exists, has not been definitively identified for the myriad immune system effects. The review then provides a summary of in vivo and in vitro effects in the immune system, in autoimmune models, with a focus on experimental autoimmune encephalomyelitis, and ends with identification of knowledge gaps. Conclusion: Overall, the data overwhelmingly support the notion that CBD is immune suppressive and that the mechanisms involve direct suppression of activation of various immune cell types, induction of apoptosis, and promotion of regulatory cells, which, in turn, control other immune cell targets.

show abstract

Section: Identification Of Cbd Receptors and Other Targetsmentioning

confidence: 91%

Section: Identification Of Cbd Receptors and Other Targetsmentioning

confidence: 99%

Immune Responses Regulated by Cannabidiol

Nichols

Kaplan

2020

Cannabis and Cannabinoid Research

199

176

View full text Add to dashboard Cite

show abstract

“…In a study by Philpott et al in 2017, osteoarthritis was induced in male Wistar rats via intra-articular injection of sodium monoiodoacetate (MIA; 3 mg). In addition to its therapeutic effect caused by a decreased joint firing rate and an increased threshold for weight-bearing, the authors demonstrate a prophylactic benefit of 100-300 mcg of CBD as evidenced by a statistically significant reduction of MIA-induced joint pain at a later time point [12]. Despite a small sample size (n = 8), these data are promising and suggest a possible role in prolonging the time course of osteoarthritis, either to the onset of clinical symptoms or to the need for pharmacologic or operative intervention.…”

Section: Clinical Utility: Cannabidiolmentioning

confidence: 81%

Cannabidiol: A Brief Review of Its Therapeutic and Pharmacologic Efficacy in the Management of Joint Disease

Gusho¹,

Court²

2020

Cureus

View full text Add to dashboard Cite

“…56 There have been several animal studies showing reductions in pain and inflammation in osteoarthritis and neuropathic pain models. 53,57,58 Given the promising animal studies and favorable safety profile, further human trials examining the efficacy of CBD for the management of acute pain and inflammation are warranted.…”

Section: Discussionmentioning

confidence: 99%

Cannabinoids in the Management of Acute Pain: A Systematic Review and Meta-analysis

Gazendam

Nucci

Gouveia

et al. 2020

Cannabis and Cannabinoid Research

View full text Add to dashboard Cite

Objective: To synthesize the best evidence surrounding the efficacy of cannabinoids for acute pain in the clinical setting based on subjective pain scores and observed adverse effects. Design: Systematic review with meta-analysis. Data Sources: PubMed, Embase, Cochrane Databases, and Google Scholar. Eligibility Criteria: English-language randomized-controlled clinical trials comparing cannabinoids with placebo in patients with acute pain. Data Extraction and Synthesis: Study quality was assessed using the Cochrane risk of bias tool. All stages were conducted independently by a team of three reviewers. Data were pooled through meta-analysis and stratified by route of administration. Primary Outcomes and Measures: Patient-reported pain and adverse events (AEs). Results: Six trials (678 participants) were included examining oral (5 trials) and intramuscular (1 trial) cannabinoids. Overall, there was a small but statistically significant treatment effect favoring the use of cannabinoids over placebo (À0.90, 95% confidence interval [CI] À1.69 toÀ0.1, i 2 = 65%, p = 0.03). When stratified by route of administration, intramuscular cannabinoids were found to have a significant reduction in pain relative to placebo (À2.98, 95% CIÀ4.09 toÀ1.87, i 2 = 0%, p < 0.0001). No difference in effect was observed between oral cannabinoids and placebo (À0.21, 95% CI À0.64 to 0.22, i 2 = 3%, p = 0.34). Serious AEs were rare, and similar across the cannabinoid (14/374, 3.7%) and placebo groups (8/304, 2.6%). Conclusions: There is low-quality evidence indicating that cannabinoids may be a safe alternative for a small but significant reduction in subjective pain score when treating acute pain, with intramuscular administration resulting in a greater reduction relative to oral. Higher quality, long-term randomized-controlled trials examining whether there may be a role for cannabinoids in treating acute pain are required.

show abstract

Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis

Abstract: The nonpsychoactive cannabis-derivative cannabidiol (CBD) reduced nociceptor activity and pain in end-stage osteoarthritis. Prophylactic treatment with CBD prevented joint neuropathy and chronic neuropathic pain.

Cited by 201 publications

References 43 publications

Immune Responses Regulated by Cannabidiol

Immune Responses Regulated by Cannabidiol

Cannabidiol: A Brief Review of Its Therapeutic and Pharmacologic Efficacy in the Management of Joint Disease

Cannabinoids in the Management of Acute Pain: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About